Scancell (LON:SCLP) Stock Price Down 3.2% - Time to Sell?

Key Points

• Scancell Holdings plc's shares fell by 3.2% on Tuesday, trading at GBX 9.69 after closing at GBX 10.
• The company has a notable debt-to-equity ratio of -566.79 and a market capitalization of £100.51 million.
• Insider Martin Diggle purchased 102,236 shares at an average price of GBX 11, reflecting a continuing insider interest in the company.

Scancell Holdings plc (LON:SCLP - Get Free Report) was down 3.2% during mid-day trading on Tuesday . The stock traded as low as GBX 9.60 ($0.13) and last traded at GBX 9.69 ($0.13). Approximately 1,336,894 shares changed hands during mid-day trading, an increase of 44% from the average daily volume of 925,977 shares. The stock had previously closed at GBX 10 ($0.13).

Scancell Stock Down 4.3%

The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42. The firm has a market capitalization of £93.40 million, a PE ratio of -432.69 and a beta of 0.35. The company's 50 day simple moving average is GBX 10.17 and its 200-day simple moving average is GBX 9.61.

Insider Activity at Scancell

In related news, insider Martin Diggle purchased 4,400,000 shares of the firm's stock in a transaction dated Friday, August 1st. The shares were purchased at an average price of GBX 10 per share, with a total value of £440,000. 14.23% of the stock is owned by insiders.

About Scancell

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.